Insight Molecular Diagnostics Inc. (IMDX)
IMDX Stock Price Chart
Explore Insight Molecular Diagnostics Inc. interactive price chart. Choose custom timeframes to analyze IMDX price movements and trends.
IMDX Company Profile
Discover essential business fundamentals and corporate details for Insight Molecular Diagnostics Inc. (IMDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
30 Dec 2015
Employees
46.00
Website
https://imdxinc.comCEO
Joshua Riggs
Description
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
IMDX Financial Timeline
Browse a chronological timeline of Insight Molecular Diagnostics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.24, while revenue estimate is $437.50k.
Earnings released on 13 May 2026
EPS came in at -$0.12 surpassing the estimated -$0.26 by +54.11%, while revenue for the quarter reached $32.00k , missing expectations by -86.04%.
Earnings released on 26 Mar 2026
EPS came in at -$0.27 falling short of the estimated -$0.24 by -13.68%, while revenue for the quarter reached $1.14m , beating expectations by +299.65%.
Earnings released on 10 Nov 2025
EPS came in at -$0.34 falling short of the estimated -$0.24 by -41.67%, while revenue for the quarter reached $260.00k , missing expectations by -8.77%.
Earnings released on 11 Aug 2025
EPS came in at -$0.30 falling short of the estimated -$0.23 by -30.43%, while revenue for the quarter reached $518.00k , beating expectations by +72.67%.
Earnings released on 12 May 2025
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $2.14m , beating expectations by +1.59k%.
Earnings released on 24 Mar 2025
EPS came in at $0.48 surpassing the estimated -$0.43 by +211.63%, while revenue for the quarter reached $1.49m , beating expectations by +837.24%.
Earnings released on 12 Nov 2024
EPS came in at -$0.98 falling short of the estimated -$0.44 by -122.73%, while revenue for the quarter reached $115.00k , beating expectations by +13.11%.
Earnings released on 8 Aug 2024
EPS came in at -$0.36 surpassing the estimated -$0.56 by +35.71%, while revenue for the quarter reached $104.00k , missing expectations by -67.50%.
Earnings released on 15 May 2024
EPS came in at -$1.13 falling short of the estimated -$0.67 by -68.66%, while revenue for the quarter reached $176.00k , missing expectations by -49.71%.
Earnings released on 12 Apr 2024
EPS came in at -$2.12 falling short of the estimated -$1.14 by -85.96%, while revenue for the quarter reached $314.00k , beating expectations by +39.56%.
Earnings released on 9 Nov 2023
EPS came in at -$0.57 surpassing the estimated -$1.52 by +62.50%, while revenue for the quarter reached $429.00k , beating expectations by +34.06%.
Earnings released on 10 Aug 2023
EPS came in at -$1.07 surpassing the estimated -$2.60 by +58.85%, while revenue for the quarter reached $463.00k , beating expectations by +28.61%.
Stock split effective on 25 Jul 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2023
EPS came in at -$0.80 surpassing the estimated -$2.40 by +66.67%, while revenue for the quarter reached $297.00k , missing expectations by -15.14%.
Earnings released on 29 Mar 2023
EPS came in at -$7.64 falling short of the estimated -$0.09 by -8.39k%, while revenue for the quarter reached -$3.55m , missing expectations by -350.00%.
Earnings released on 10 Nov 2022
EPS came in at -$1.60 surpassing the estimated -$2.60 by +38.46%, while revenue for the quarter reached $1.02m , missing expectations by -31.50%.
Earnings released on 10 Aug 2022
EPS came in at -$1.40 surpassing the estimated -$2.60 by +46.15%, while revenue for the quarter reached $2.07m , missing expectations by -23.60%.
Earnings released on 11 May 2022
EPS came in at -$2.20 surpassing the estimated -$2.60 by +15.38%, while revenue for the quarter reached $1.42m , missing expectations by -36.48%.
Earnings released on 10 Mar 2022
EPS came in at -$2.00 matching the estimated -$2.00, while revenue for the quarter reached $3.59m , beating expectations by +1.85%.
Earnings released on 9 Nov 2021
EPS came in at -$2.20 falling short of the estimated -$1.40 by -57.14%, while revenue for the quarter reached $984.00k , missing expectations by -43.88%.
Earnings released on 10 Aug 2021
EPS came in at -$1.60 matching the estimated -$1.60, while revenue for the quarter reached $2.03m , beating expectations by +29.30%.
IMDX Stock Performance
Access detailed IMDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
